Followers | 1424 |
Posts | 86,803 |
Boards Moderated | 0 |
Alias Born | 02/01/2005 |
Twitter Profile: | Temporarily Unavailable |
Follow on Twitter: | Follow @ Temporarily Unavailable |
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$BIXT Galectin Therapeutics (GALT) A Discount Opportunity Moving on Analysts Upgrade
https://www.insiderfinancial.com/post/galectin-therapeutics-galt-a-discount-opportunity-moving-on-analysts-upgrade
$GALT #MDGL #galectin #antiviral
$BIXT Galectin Therapeutics (GALT) A Discount Opportunity Moving on Analysts Upgrade
https://www.insiderfinancial.com/post/galectin-therapeutics-galt-a-discount-opportunity-moving-on-analysts-upgrade
$GALT #MDGL #galectin #antiviral
$DBGI CEO CONFIRMED NO EQUITY OFFERING IN 2024
FLOAT ONLY 980K,
THIS CAN ROCKET AT ANY MOMENT, HIT $12.80 UPON PR CONFIRMING NO 2024 OFFERINGS
NO FEAR OF DILUTION, JUST LOW FLOAT MAGIC!
https://www.prnewswire.com/news-releases/dbgi-reaffirms-its-2024-guidance-and-commits-to-no-equity-offerings-for-2024-302060320.html
$DBGI CEO CONFIRMED NO EQUITY OFFERING IN 2024
FLOAT ONLY 980K,
THIS CAN ROCKET AT ANY MOMENT, HIT $12.80 UPON PR CONFIRMING NO 2024 OFFERINGS
NO FEAR OF DILUTION, JUST LOW FLOAT MAGIC!
https://www.prnewswire.com/news-releases/dbgi-reaffirms-its-2024-guidance-and-commits-to-no-equity-offerings-for-2024-302060320.html
$HUGE : do not overlook UNBUZZD, accelerates the metabolism of alcohol, restores mental alertness, and improves cognition post-alcohol consumption
More to come, much more.
https://www.fsdpharma.com/
$HUGE : do not overlook UNBUZZD, accelerates the metabolism of alcohol, restores mental alertness, and improves cognition post-alcohol consumption
More to come, much more.
https://www.fsdpharma.com/
$HUGE OPPORTUNITY TO BUY LOW !! UNDERVALUED AND OVERLOOKED---THE DETOX BEVERAGE INDUSTRY WILL BE #HUGE
β’oversold and undervalued-RSI=41
β’UNBUZZD product shortens the time to lower Breath Alcohol Content (BrAC)
β’Lucid-MS achieved positive results against MS
https://www.fsdpharma.com/
$HUGE OPPORTUNITY TO BUY LOW !! UNDERVALUED AND OVERLOOKED---THE DETOX BEVERAGE INDUSTRY WILL BE #HUGE
β’oversold and undervalued-RSI=41
β’UNBUZZD product shortens the time to lower Breath Alcohol Content (BrAC)
β’Lucid-MS achieved positive results against MS
https://www.fsdpharma.com/
$AGBA~ AGBA CEO PUTTING HIS MONEY WHERE HIS MOUTH IS $$$$$
$AGBA YOU MUST SEE THIS
🔥CEO, Mr. Wing-Fai Ng buys over $2.5M in private placement at a premium .70 !
🔥Mr. Wing-Fai Ng, "We're going to charge ahead. We're going to put money where our mouth is"
$AGBA~ AGBA CEO PUTTING HIS MONEY WHERE HIS MOUTH IS $$$$$
$AGBA YOU MUST SEE THIS
🔥CEO, Mr. Wing-Fai Ng buys over $2.5M in private placement at a premium .70 !
🔥Mr. Wing-Fai Ng, "We're going to charge ahead. We're going to put money where our mouth is"
$AGBA Mr. Wing-Fai Ng, CEO buying over $2,500,000 of this private placement at .70 is extremely bullish!
Mr. Wing-Fai Ng, quote from recent Emerging Growth Conference, "We're going to charge ahead. We're going to put money where our mouth is."
https://agba.com/media/2024/03/AGBA-Research-Report-March-2024.pdf
$AGBA Mr. Wing-Fai Ng, CEO buying over $2,500,000 of this private placement at .70 is extremely bullish!
Mr. Wing-Fai Ng, quote from recent Emerging Growth Conference, "We're going to charge ahead. We're going to put money where our mouth is."
https://agba.com/media/2024/03/AGBA-Research-Report-March-2024.pdf
$HUGE OPPORTUNITY TO BUY LOW !!
β’oversold and undervalued-RSI=41
β’UNBUZZD product shortens the time to lower Breath Alcohol Content (BrAC)
β’Lucid-MS achieved positive results against MS
https://www.fsdpharma.com/unbuzzd
$HUGE OPPORTUNITY TO BUY LOW !!
β’oversold and undervalued-RSI=41
β’UNBUZZD product shortens the time to lower Breath Alcohol Content (BrAC)
β’Lucid-MS achieved positive results against MS
https://www.fsdpharma.com/unbuzzd
$AGBA : Mr. Wing-Fai Ng, CEO -"We are number one by far.......... we have about half a million customers in this region. Again, we are led by a fantastic team in Hong Kong "
Price - "this is extremely important for us as many of us own shares inside the company, and we know you- our audience owns a lot of shares. Company share price means a lot to us and we are very focused on this."
$AGBA : Mr. Wing-Fai Ng, CEO -"We are number one by far.......... we have about half a million customers in this region. Again, we are led by a fantastic team in Hong Kong "
Price - "this is extremely important for us as many of us own shares inside the company, and we know you- our audience owns a lot of shares. Company share price means a lot to us and we are very focused on this."
$BIXT: Terminating the Viral Threat with Artificial Intelligence - Myth or Reality
https://www.zerohedge.com/news/2024-03-11/terminating-viral-threat-artificial-intelligence-myth-or-reality
$BIXT: Terminating the Viral Threat with Artificial Intelligence - Myth or Reality
https://www.zerohedge.com/news/2024-03-11/terminating-viral-threat-artificial-intelligence-myth-or-reality
$AGBA #FINTECH COMPANY VALUED AT $555M IN 2022
COMPANY CURRENTLY ON SALE FOR $26M !!
https://agba.com
@agbagroup
PROFIT FROM IT!
LOAD THE DIP!
β’SEVERE MARKET DISCONNECT
$AGBA #FINTECH COMPANY VALUED AT $555M IN 2022
COMPANY CURRENTLY ON SALE FOR $26M !!
https://agba.com
@agbagroup
PROFIT FROM IT!
LOAD THE DIP!
β’SEVERE MARKET DISCONNECT
$AGBA USA WOW! COMING TO AMERICA! ( REDOMICILE)
Mr. Wing-Fai Ng, CEO , "You should expect we're going to be much more aggressive this year when it comes to acquisitions, and we have a few."
#wealthmanagement #financialadvisor #healthcareworkers
$AGBA USA WOW! COMING TO AMERICA! ( REDOMICILE)
Mr. Wing-Fai Ng, CEO , "You should expect we're going to be much more aggressive this year when it comes to acquisitions, and we have a few."
#wealthmanagement #financialadvisor #healthcareworkers
$AGBA : Mr. Wing-Fai Ng, CEO -"We are number one by far. We have a very unique franchise that we can spend a lot of time talking about our franchise strength, and we have about half a million customers in this region. Again, we are led by a fantastic team in Hong Kong that has been doing this for a very long time, and we're very proud of it.
-So, on one hand, we have the largest business in Hong Kong that sells everything under the sun in financial services for retail customers. On the other hand, of our business, we also have one of the largest healthcare franchises in the region."
3.Price - "this is extremely important for us as many of us own shares inside the company, and we know you- our audience owns a lot of shares. Company share price means a lot to us and we are very focused on this."
$AGBA : Mr. Wing-Fai Ng, CEO -"We are number one by far. We have a very unique franchise that we can spend a lot of time talking about our franchise strength, and we have about half a million customers in this region. Again, we are led by a fantastic team in Hong Kong that has been doing this for a very long time, and we're very proud of it.
-So, on one hand, we have the largest business in Hong Kong that sells everything under the sun in financial services for retail customers. On the other hand, of our business, we also have one of the largest healthcare franchises in the region."
3.Price - "this is extremely important for us as many of us own shares inside the company, and we know you- our audience owns a lot of shares. Company share price means a lot to us and we are very focused on this."
#AGBA 🔥Mr. Wing-Fai Ng, CEO
EMERGING GROWTH CONFERENCE!!
🔥THIS IS A MUST WATCH VIDEO
🔥THIS COULD CHANGE YOUR FINANCIAL FUTURE!
#wealthmanagement #financialadvisor #healthcare
$AGBA 🔥Mr. Wing-Fai Ng, CEO
EMERGING GROWTH CONFERENCE!!
🔥THIS IS A MUST WATCH VIDEO
🔥THIS COULD CHANGE YOUR FINANCIAL FUTURE!
#wealthmanagement #financialadvisor #healthcare
$HUGE: FSD Pharma Submits a Phase-1b Clinical Trial Application for Ethics Committee for its Proprietary Beverage unbuzzd™
TORONTO, ON / ACCESSWIRE / March 11, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, today announces the submission of the Company's Clinical Trial Application (CTA) for a planned Phase-1b clinical trial to Assess the Safety and Efficacy of unbuzzd™ in Healthy Volunteers in an Induced State of Alcohol Intoxication (METAL-1 TRIAL). This clinical trial application is submitted for review by a human ethics review committee ("HREC") in Australia, a first step to obtain permission to initiate the clinical trial. Recruitment of healthy volunteers to this trial is expected to begin this April, following approval by the HREC.
unbuzzd™ is the dietary supplement product under development for potential marketing in the United States. unbuzzd™ is a fortified oral liquid formula with natural ingredients, vitamins and other food supplements that potentially enhances cognition, replenishes cofactors needed for alcohol metabolism, and has the shown to accelerate the rate of alcohol metabolism in the body.
"This marks the culmination of several months of intense work by the FSD team and by our expert advisors, conceptualizing and designing this meaningful clinical trial to assess the safety and efficacy of this exciting product on people who drink alcohol. We look forward to working closely and swiftly with our Australian partners and the ethics committee on this project," said Dr. Andrzej Chruscinski, Vice-President, Scientific and Clinical Affairs at FSD Pharma.
John Duffy the current CEO of Celly Nutrition said, "unbuzzd™ has been developed to accelerate the metabolism of alcohol, restore mental alertness, and improve cognition post-alcohol consumption. This development has been based on science alone, the Phase-1b clinical trial is another example of FSD Pharma Inc.'s commitment to the efficacy of unbuzzd™. The Celly Nutrition team looks forward to bringing this cutting-edge innovation to consumers across the United States."
John Duffy, among other companies, previously worked for Coca-Cola (NYSE: KO) for 22+ years, including serving as Vice President for national sales for Coca-Cola.
Gerry David, CEO (retired) of Celsius Energy drink (Nasdaq: CELH) stated that "I truly see unbuzzd™ as a product that will affect so many lives in such a positive way. I look forward to helping make unbuzzd™ a mainstream success."
About FSD Pharma
FSD Pharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly-owned subsidiary, Lucid Psycheceuticals Inc. ("Lucid"), FSD is focused on the research and development of its lead compound, Lucid-MS (formerly Lucid-21-302) ("Lucid-MS"). Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. FSD Pharma has also licensed unbuzzd™, a proprietary formulation of natural ingredients, vitamins, and minerals to help with liver and brain function for the purposes of quickly relieving individuals from the effects of alcohol consumption for use in the consumer recreational sector, to Celly Nutrition Corp. ("Celly Nu") and is entitled to a royalty on the revenue generated by Celly Nu from sales of products created using the technology rights granted under the licensing agreement. FSD Pharma continues its R&D activities to develop novel formulations for alcohol misuse disorders and continues the development of such treatments for use in the healthcare sector. FSD maintains a portfolio of strategic investments through its wholly-owned subsidiary, FSD Strategic Investments Inc., which represent loans secured by residential or commercial property.
https://accesswire.com/841153/fsd-pharma-submits-a-phase-1b-clinical-trial-application-for-ethics-committee-for-its-proprietary-beverage-unbuzzdtm
$HUGE: FSD Pharma Submits a Phase-1b Clinical Trial Application for Ethics Committee for its Proprietary Beverage unbuzzd™
TORONTO, ON / ACCESSWIRE / March 11, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, today announces the submission of the Company's Clinical Trial Application (CTA) for a planned Phase-1b clinical trial to Assess the Safety and Efficacy of unbuzzd™ in Healthy Volunteers in an Induced State of Alcohol Intoxication (METAL-1 TRIAL). This clinical trial application is submitted for review by a human ethics review committee ("HREC") in Australia, a first step to obtain permission to initiate the clinical trial. Recruitment of healthy volunteers to this trial is expected to begin this April, following approval by the HREC.
unbuzzd™ is the dietary supplement product under development for potential marketing in the United States. unbuzzd™ is a fortified oral liquid formula with natural ingredients, vitamins and other food supplements that potentially enhances cognition, replenishes cofactors needed for alcohol metabolism, and has the shown to accelerate the rate of alcohol metabolism in the body.
"This marks the culmination of several months of intense work by the FSD team and by our expert advisors, conceptualizing and designing this meaningful clinical trial to assess the safety and efficacy of this exciting product on people who drink alcohol. We look forward to working closely and swiftly with our Australian partners and the ethics committee on this project," said Dr. Andrzej Chruscinski, Vice-President, Scientific and Clinical Affairs at FSD Pharma.
John Duffy the current CEO of Celly Nutrition said, "unbuzzd™ has been developed to accelerate the metabolism of alcohol, restore mental alertness, and improve cognition post-alcohol consumption. This development has been based on science alone, the Phase-1b clinical trial is another example of FSD Pharma Inc.'s commitment to the efficacy of unbuzzd™. The Celly Nutrition team looks forward to bringing this cutting-edge innovation to consumers across the United States."
John Duffy, among other companies, previously worked for Coca-Cola (NYSE: KO) for 22+ years, including serving as Vice President for national sales for Coca-Cola.
Gerry David, CEO (retired) of Celsius Energy drink (Nasdaq: CELH) stated that "I truly see unbuzzd™ as a product that will affect so many lives in such a positive way. I look forward to helping make unbuzzd™ a mainstream success."
About FSD Pharma
FSD Pharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly-owned subsidiary, Lucid Psycheceuticals Inc. ("Lucid"), FSD is focused on the research and development of its lead compound, Lucid-MS (formerly Lucid-21-302) ("Lucid-MS"). Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. FSD Pharma has also licensed unbuzzd™, a proprietary formulation of natural ingredients, vitamins, and minerals to help with liver and brain function for the purposes of quickly relieving individuals from the effects of alcohol consumption for use in the consumer recreational sector, to Celly Nutrition Corp. ("Celly Nu") and is entitled to a royalty on the revenue generated by Celly Nu from sales of products created using the technology rights granted under the licensing agreement. FSD Pharma continues its R&D activities to develop novel formulations for alcohol misuse disorders and continues the development of such treatments for use in the healthcare sector. FSD maintains a portfolio of strategic investments through its wholly-owned subsidiary, FSD Strategic Investments Inc., which represent loans secured by residential or commercial property.
https://accesswire.com/841153/fsd-pharma-submits-a-phase-1b-clinical-trial-application-for-ethics-committee-for-its-proprietary-beverage-unbuzzdtm
$AGBA~ AGBA~ expecting press Monday / Tuesday
$AGBA~ AGBA~ expecting press Monday / Tuesday$BBAI $SOUN $NVDA $SHOT $KTRA $AREN $ROI $BK $BEN $JHG $AB $APAM $APO $FDUS $ARES #AGBA #Allgreatertogether #Nasdaq $AGBA #insurance #investment #HongKong #China #GreaterBayArea #health #WealthManagement @realsheepwolfβ¦
— TDogzz πΊπ²π΄ (@jctb1) March 8, 2024
$AGBA~ AGBA~ expecting press Monday / Tuesday
$AGBA~ AGBA~ expecting press Monday / Tuesday$BBAI $SOUN $NVDA $SHOT $KTRA $AREN $ROI $BK $BEN $JHG $AB $APAM $APO $FDUS $ARES #AGBA #Allgreatertogether #Nasdaq $AGBA #insurance #investment #HongKong #China #GreaterBayArea #health #WealthManagement @realsheepwolfβ¦
— TDogzz πΊπ²π΄ (@jctb1) March 8, 2024
$AGBA 🔥Mr. Wing-Fai Ng, CEO
EMERGING GROWTH CONFERENCE!!
🔥THIS IS A MUST WATCH VIDEO
🔥THIS COULD CHANGE YOUR FINANCIAL FUTURE!
$AGBA 🔥Mr. Wing-Fai Ng, CEO
EMERGING GROWTH CONFERENCE!!
🔥THIS IS A MUST WATCH VIDEO
🔥THIS COULD CHANGE YOUR FINANCIAL FUTURE!